-
Blog BLOG
-
Product Center BRAND DYNAMICS
-
Investor INVESTOR RELATIONS
-
Contact Us CONTACT
-
Supervise SUPERVISION
Latest progress revealed: The phase III clinical trial of the Lizhu COVID-19 vaccine V-01 sequential booster is undergoing interim data analysis.
Published Time:
2022-02-15
Recently, during an investor relations meeting, Lizhu Group announced that the overseas Phase III clinical trial of its recombinant protein COVID-19 vaccine, V-01, has completed subject enrollment and endpoint case collection in some countries. The Phase III clinical trial conducted in Pakistan and Malaysia as a third-dose sequential booster based on an inactivated vaccine has reached the interim analysis target set in the protocol, and the interim data analysis is currently underway. The Phase III clinical trial for basic immunization has also reached the interim analysis target set in the protocol, and data cleaning and preparation for interim analysis are actively underway.
It is understood that the COVID-19 vaccine V-01 is a recombinant protein vaccine jointly developed by Lizhu Bio and the Chinese Academy of Sciences. In addition to its many advantages, including low biosafety level requirements for production facilities, high purity, better safety, high yield, low cost, and rapid development of new vaccines targeting variants, V-01 also uses conventional aluminum adjuvant, with a stable and sufficient supply chain and a production capacity of 1.5 billion doses. Phase II clinical trial data for the V-01 vaccine was published in the Chinese Medical Journal in July 2021. The results showed that the vaccine has excellent immunogenicity and safety, especially with a lower overall incidence of vaccine-related adverse events in the elderly group compared to the adult group. The Phase III sequential booster clinical trial of V-01 was launched in Pakistan in October 2021. Based on current progress, this vaccine should be the first and fastest domestically developed vaccine to undergo a formal sequential immunization Phase III clinical trial overseas.
If the Phase III clinical trial of the V-01 vaccine yields positive results, it is expected to accelerate the market launch process and may be strongly promoted as a superior booster option.
(This article does not constitute any investment advice. Information disclosure is subject to the company's announcements. Investors operate at their own risk.)
Source: Daily Economic News
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
Sorry,当前栏目暂无内容!
您可以查看其他栏目或返回 首页
Sorry,The current column has no content!
You can view other columns or return Home